Search
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 1 of 1 items.
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03